See the article here:
CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh